<DOC>
	<DOCNO>NCT01745445</DOCNO>
	<brief_summary>This trial aim evaluate efficacy safety radiotherapy alone concurrent chemo-radiotherapy 3-4 cycle chemotherapy LS-SCLC .</brief_summary>
	<brief_title>Clinical Randomized Study Concurrent Chemo-radiotherapy v Radiotherapy Alone Local-advanced Small Cell Lung Cancer ( SCLC )</brief_title>
	<detailed_description>Small cell lung cancer ( SCLC ) represent 15-30 % lung malignancy China . Limited-stage small cell lung cancer ( LS-SCLC ) represent approximately 40 % case . The current standard care limited-stage disease systemic chemotherapy plus concurrent thoracic radiotherapy . Early concurrent chemo-radiotherapy recommend patient limited-stage SCLC base randomized trial . But , administration thoracic radiotherapy require assessment several factor , include volume radiation port , dose radiation , fractionation radiotherapy . Parts LS-SCLC local advanced stage ( stage Ⅲa Ⅲb ) , tolerate concurrent chemo-radiotherapy large size tumor extensive metastasis lymph node . At present , usually use 3-4 cycle introduction chemotherapy decrease tumor size follow definitive radiotherapy . But unclear whether scheme tolerant well could improve overall survival patient LS-SCLC . As result , design prospective phase II randomize control trial order compare tolerance therapeutic effect radiotherapy alone concurrent chemo-radiotherapy 3-4 cycle chemotherapy LS-SCLC .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<criteria>Age 18 75 year ; ECOG performance status 0 1 ; Pathological cytological confirmation SCLC ; Local stage small cell lung cancer stage Ⅲa Ⅲb ; Receive 34 cycle chemotherapy etoposide plus cisplatin ; Measurable disease use RECIST criterion least one lesion ; Adequate hematological , renal , hepatic pulmonary function define : granulocyte ≥ 2.0×109/L , platelet ≥ 100 x 109/L , hemoglobin ≥ 8g/L , total bilirubin ≤ 1.5 x upper normal limit , aspartate aminotransferase , alanine aminotransferase≤2.5 × upper normal limit , , creatinine ≤ 1.5mg/L , FEV1 ≥ 1.5 L Ability understand willingness sign write informed consent form ; History operation lung cancer ; PD 34 cycle chemotherapy ; Patients sever infection ; Patients uncontrollable diabetes ; Patients pregnancy lactation ; Patients currently receive receive clinical trail radioprotection within prior six month exclude ; Patient history malignancy skin cancer Carcinoma insitu within 2 year ; History cardiovascular disease might include one follow : myocardial infraction , angina , coronary angioplasty , congestive heart failure , stroke , coronary bypass surgery last 6 month ; Concomitant treatment anticancer drug ;</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>limited-stage small cell lung cancer</keyword>
	<keyword>concurrent chemo-radiotherapy</keyword>
</DOC>